Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

Blood

Volumn 107, Issue 9, 2006, Pages 3575-3583

  Blanco, Belén ^a   Pérez Simón, José A ^a   Sánchez Abarca, Luis I ^a   Carvajal Vergara, Xonia ^a   Mateos, Juan ^a   Vidriales, Belén ^a   López Holgado, Natalia ^a   Maiso, Patricia ^a   Alberca, Mercedes ^a   Villarón, Eva ^a   Schenkein, David ^a   Pandiella, Atanasio ^a   San Miguel, Jesús ^a  

^a Centro de Investigacion del Cancer   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; PROTEIN BCL 2;

ALLOIMMUNITY; APOPTOSIS; ARTICLE; BLOOD COMPATIBILITY; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 33646421393     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2118     Document Type: Article

References (40)

1. Ghosh S, May M, Koppp E. NF-κB and Rel proteins: evolutionary conserved mediators to immune responses. Annu Rev Immunol. 1998;16:225-260.
2. O'Sullivan B, Thomas R. CD40 ligation conditions dendritic cells antigen-presenting function through sustained activation of Nf-κB. J Immunol. 2002;168:5491-5498.
3. Matsumoto M, Yamada T, Yoshinaga S, et al. Essential role of NF-κB inducing kinase in T cell activation through the CDR/CD3 pathway. J Immunol. 2002;169:1151-1158.
4. Andreakos E, Smith C, Monaco C, et al. IκB kinase 2 but not NF-κB inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocytes reaction. Blood. 2003;101:983-991.
5. Jun J, Goodnow C. Scaffolding of antigen receptors for immmunogenic versus tolerogenic signaling. Nat Immunol. 2003;4:1057-1064.
6. Masuda E, Imamura R, Amasaki Y, Arai K, Arai N. Signalling into the T-cell nucleus: NFAT regulation. Cell Signal. 1998;10:599-611.
7. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell. 2002;109:719-731.
8. Sundstedt A, Sigvardsson M, Leanderson T, et al. In vivo anergized CD4+T cells express perturbed AP-1 and NF-κB transcription factors. Proc Natl Acad Sci U S A. 1996;93:979-984.
9. Xanthoudakis S, Viola JP, Shaw KT, et al. An enhaced immune response in mice lacking the transcription factor NFAT1 [erratum]. Science. 1996;273:1325.
10. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
11. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
12. Li B, Dou Q. Bax degradation by the ubiquitin/proteasome dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A. 2000;97:3835-3855.
13. Palombella V, Rando O, Goldberg A, Maniatis T. The ubiquitin proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. 1994;78:773-785.
14. Mitsiades N, Mitsiades C, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
15. Esparis-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer. 2005;114:665-667.
16. Martino R, Caballero D, Perez-Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100:2243-2245.
17. Pérez-Simón JA, Martino R, Alegre A, et al. Chronic but not acute graft versus host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation. Br J Hematol. 2003;121:104-108.
18. Michálek J, Collins RH, Durrani HP, et al. Definitive separation of graft versus leukemia and graft versus host specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A. 2003;100:1180-1184.
19. Sun K, Welniak L, Panoskaltsis-Mortari A, et al. Inhibition of acute graft versus host disease with retention of graft versus tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A. 2004;101:8120-8125.
20. Almeida J, Bueno C, Alguero MC, et al. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHCII+-/lineage-cells. Clin Exp Immunol. 1999;118:392-401.
21. Reddy M, Eirikis E, Davis C, Davis H, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004;293:127-142.
22. Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877-3886.
23. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chain (CD25): breakdown of a single mechanism of self tolerance causes various autoimmune diseases. J Immunol. 1996;155:1151-1164.
24. Martin PJ, Pei J, Gooley T, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10:552-560.
25. Davies JK, Koh MB, Lowdell MW. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant. 2004;10:259-268.
26. Weil R, Israël A. T-cell receptor and B-cell receptor mediated activation of NF-κB in lymphocytes. Curr Opin Immunol. 2004;16:374-381.
27. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 1999;18:6910-6924.
28. Catz SD, Jonson JL. Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. Oncogene. 2001;20:7342-7351.
29. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor induced cell death by inhibitor of apoptosis cIAP2 is under NF-κB control. Proc Natl Acad Sci U S A. 1997;94:10057-10062.
30. Monney L, Otter I, Olivier B, et al. Defects in the ubiquitin pathway induce caspase-independent apoptosis blocked by bcl-2. J Biol Chem. 1998;273:6121-6131.
31. Kriehuber E, Bauer W, Charbonnier A-S, et al. The balance between NF-κB and JNK/AP-1 activity controls dendritic cell life and death. Blood. Prepublished on March 8, 2005, as DOI 10.1182/blood-2004-08-3072.
32. (Now available as Blood. 2005;106:175-183.)
33. Sun K, Wilkins DEC, Anver MR, et al. Differential effects of proteosome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. Prepublished on June 16, 2005, as DOI 10.1182/blood-2004-11-4526.
34. (Now available as Blood. 2005;106:3293-3299.)
35. Pérez-Simón JA, Díez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Hematol. 2005;130:394-403.
36. Reddy M, Eirikis E, Davis C, Davis H, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004;293:127-142.
37. Zhou X, Yashiro-Ohtani Y, Nakahira M, et al. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol. 2002;168:3847-3854.
38. Rao A, Luo C, Hogan P. Transcription factors of the NFAT family: regulation and function. Ann Rev Immunol. 1997;15:707-747.
39. + regulatory T cells. Prepublished on March 3, 2005, as DOI 10.1182/blood-2004-10-3932.
40. (Now available as Blood. 2005;105:4743-4748.)